RT Journal Article SR Electronic T1 IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.15.20103531 DO 10.1101/2020.05.15.20103531 A1 Lucas M. Kimmig A1 David Wu A1 Matthew Gold A1 Natasha N Pettit A1 David Pitrak A1 Jeffery Mueller A1 Aliya N. Husain A1 Ece A. Mutlu A1 Gökhan M. Mutlu YR 2020 UL http://medrxiv.org/content/early/2020/05/20/2020.05.15.20103531.abstract AB Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and predispose to secondary infection. To determine whether IL-6 inhibition is associated with an increased occurrence of secondary infections in patients admitted to the intensive care unit (ICU). We retrospectively reviewed the medical record of patients during an 8-week span and compared the incidence of secondary infection in patients who did and did not receive tocilizumab. The study was approved by the IRB. Additionally, we included representative histopathologic post-mortem findings from several COVID-19 cases that underwent autopsy at our institution. The study was conducted in a cohorted COVID-19 ICU at a tertiary care university medical center. Patients 18 years of age or older admitted to the adult COVID-19 intensive care unit with COVID-19 were randomly selected. We reviewed the occurrence and nature of secondary infections and clinical outcomes in patients who did and did not receive tocilizumab. Measures were formulated prior to the study. For autopsy findings, we were interested in the lung pathology. 60 patients were selected of which 28 had received tocilizumab while 32 had not. Receiving tocilizumab was associated with a higher risk of secondary bacterial (64.3% vs. 31.3%, p=0.010) and fungal (7.1% vs. 0%, p=0.096) infections. 7 cases underwent autopsy. In 3 cases, tocilizumab had previously been given. All 3 patients demonstrated evidence of pneumonia on pathology. Of the 4 cases that had not been given tocilizumab, 2 showed evidence of aspiration pneumonia and 2 exhibited diffuse alveolar damage. Experimental therapies are currently being applied to COVID-19 outside of clinical trials. Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, predispose to secondary infection, and cause harm. We seek to raise physician awareness of these issues and highlight the need to better understand the immune response in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon responsible request by contacting the corresponding author.